Juan Moises Gutierrez, MD
General Practice · Miami, FLNPI 1659892693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Reporting peaked in 2023 at $129 and has fallen 56.2% since, to $57 in 2024. That places this record below the midpoint for general practice clinicians in FL, where the typical reported total is $253.
Across 13 payments — averaging $18.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phadia US Inc.$135
- Exact Sciences$103
Across 50 payments — averaging $39,659 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.7M
- Chiesi USA, Inc.$278K
- Genentech, Inc.$2K
What the payments were for
- Food & beverage$237100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phadia US Inc. | 8 | $135 |
| Exact Sciences | 5 | $103 |
How this compares
$237 in reported general payments places this provider in the 45th percentile of 6,901 general practice providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 173 | $94,579 |
| XareltoRivaroxaban | 64 | $37,406 |
| TrulicityDulaglutide | 35 | $36,838 |
| EntrestoSacubitril/Valsartan | 23 | $15,768 |
| SantylCollagenase Clostridium Hist. | 51 | $15,746 |
| JanuviaSitagliptin Phosphate | 17 | $12,645 |
| LinzessLinaclotide | 20 | $10,774 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,806 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $6,975 |
| TradjentaLinagliptin | 12 | $6,191 |
| Atorvastatin Calcium | 766 | $6,064 |
| Epinephrine | 14 | $5,914 |
| FiaspInsulin Aspart (Niacinamide) | 20 | $5,660 |
| TresibaInsulin Degludec | 16 | $5,621 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $4,516 |
Paid to pharmacies, not to this prescriber.
Other general practice in Miami
- Idalia AcostaMiami$99K
- Eddie GomezMiami$59K
- Aladino ValienteMiami$24K
- Viviana WaichMiami$20K
- Libia RiosMiami$15K
- Jose CardonaMiami$15K
- Rosa HuguetMiami$15K
- Robert VogelPalm Beach Gardens$1M
- Bruce OuelletteWest Palm Beach$724K
- Caley CasteleinMiami Beach$586K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.